ArriVent BioPharma, Inc. (AVBP): Depreciation & Amortization

Annual figures by period end, from SEC filings.

-$3.03M

Year ended 2025-12-31

Period ended	Depreciation & Amortization	Change YoY	Source filing
2025-12-31	-$3.03M	n/a	2026-03-05, From 2025-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Depreciation & Amortization	Change YoY
ArriVent BioPharma, Inc. (AVBP)	2025-12-31	-$3.03M	n/a
Rocket Pharmaceuticals, Inc. (RCKT)	2025-12-31	$8.90M	+23.6%
Liquidia Corp (LQDA)	2025-12-31	$1.53M	-30.5%
ARS Pharmaceuticals, Inc. (SPRY)	2025-12-31	$1.37M	n/m
Prothena Corp Public Ltd Co (PRTA)	2025-12-31	$895.0K	+0.2%
Lyell Immunopharma, Inc. (LYEL)	2025-12-31	$11.54M	-41.2%
Omeros Corp (OMER)	2025-12-31	$1.00M	0.0%
Atea Pharmaceuticals, Inc. (AVIR)	2025-12-31	$416.0K	0.0%
Upstream Bio, Inc. (UPB)	2025-12-31	$188.0K	+111.2%

Compare AVBP, RCKT, LQDA, SPRY side by side · Screen every company in Pharmaceutical Preparations ↗